AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ImmunoGen Announces Webcast of Presentation at the Piper Jaffray 31st Annual Healthcare Conference

November 26, 2019 GMT

WALTHAM, Mass.--(BUSINESS WIRE)--Nov 26, 2019--

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare Conference. The fireside chat is scheduled for 12:30 p.m. ET on December 3, 2019.

A webcast of the fireside chat will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005127/en/

CONTACT: INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.comORFTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: ImmunoGen, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 04:30 PM/DISC: 11/26/2019 04:30 PM

http://www.businesswire.com/news/home/20191126005127/en